![](\"https:\/\/mms.businesswire.com\/media\/20260721460381\/en\/2856253\/5\/FairJourneyBio-Logo%2BClaim_RGB_NEW_2026.jpg\")
<\/a><\/a>\nChaired by Dr Laura Walker, Executive Director of Therapeutic Immunology and Protein Engineering at Moderna and co-chaired by Dr John Desjarlais, Chief Scientific Officer of Xencor, Inc., the 2026 program has been curated to showcase the rapid pace of innovation across antibody science and engineering. The speaker line-up includes leading experts from academia and industry, including Dr George Georgiou (UT Austin), Dr Robert Seder (NIH), Professor Sarel Fleishman (Weizmann Institute of Science and Scala Biodesign) and Dr Jo Viney (Seismic Therapeutic).<\/p>
\nLaunched in 2021, TAS is a recognized annual forum that facilitates knowledge sharing and strategic collaboration across the global antibody community. Attendance is by registration of interest and invitation only, creating a focused platform for scientific leaders to share pioneering research, emerging technologies, and applications redefining the sector. To register interest in attending or to receive early access to on-demand lectures and session recordings, visit: https:\/\/antibodyseries.com\/get-involved\/<\/a>.<\/p> \nDr Werner Lanthaler, Chief Executive Officer, FairJourney Bio, commented:<\/b> \u201cBuilding on the success of previous TAS events, we are excited to announce the program for TAS 2026 and the involvement of science- and industry-leaders, Dr Walker and Dr Desjarlais. TAS offers an invaluable opportunity for science and technology to converge, delivering real value to scientific leaders across the sector and fostering the ideas and collaborations that will shape the future of Biologics.\u201d<\/i><\/p> \n\u201cThe Antibody Series has become an important forum where academic and industry communities come together around the key questions shaping antibody discovery,\u201d <\/i>added Dr Laura Walker, Executive Director of Therapeutic Immunology and Protein Engineering, Moderna.<\/b> \u201cWhat stands out about this year\u2019s program is how well it reflects where the field is moving: computational antibody design, novel multispecific formats, and next-generation therapeutic strategies. We have brought together speakers who are helping define how future antibody therapeutics will be discovered, engineered, and developed. For anyone working at the frontier of this space, this is a meeting worth attending.\u201d<\/i><\/p> \nTo find out more about TAS 2026, including the full program and confirmed speaker line-up, please visit: https:\/\/antibodyseries.com<\/a>.<\/p> \nNotes to editors<\/strong><\/p> \nThe Antibody Series (TAS) 2026 is supported by leading industry partners, including Benchling, INFORS HT, RNACoreX, Sapio Sciences, and Thermo Fisher Scientific.<\/p> \nFor further information, please contact:<\/b>